Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 511-517

  Peyrl, Andreas ^a   Chocholous, Monika ^a   Kieran, Mark W ^b   Azizi, Amedeo A ^a   Prucker, Christina ^a   Czech, Thomas ^a   Dieckmann, Karin ^a   Schmook, Maria Theresa ^a   Haberler, Christine ^c   Leiss, Ulrike ^a   Slavc, Irene ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antiangiogenic therapy; ATRT; CNS PNET; Medulloblastoma; Pineoblastoma; Recurrent embryonal tumors

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CELECOXIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FENOFIBRATE; LENALIDOMIDE; THALIDOMIDE;

ADOLESCENT; ADULT; ANTIANGIOGENIC THERAPY; ARACHNOIDITIS; ARTICLE; ATYPICAL TERATOID RHABDOID TUMOR; BRAIN TUMOR; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBRYONAL TUMOR WITH ABUNDANT NEUROPHIL AND TRUE ROSETTE; EMBRYONAL TUMOR WITH ABUNDANT NEUROPIL AND TRUE ROSETTE; EVENING DOSAGE; EVENT FREE SURVIVAL; FEMALE; HEADACHE; HEMATURIA; HUMAN; HYPOTHYROIDISM; INFANT; INTRACRANIAL HYPERTENSION; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PAPILLEDEMA; PERIPHERAL NEUROPATHY; PINEOBLASTOMA; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; REFRACTORY PERIOD; SCHOOL CHILD; TUMOR BLEEDING; TUMOR GROWTH; TUMOR RECURRENCE;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; RECURRENCE; YOUNG ADULT;

EID: 84863883498     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24006     Document Type: Article

References (40)

1. Tait DM, Thornton-Jones H, Bloom HJ, et al. Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the international society of paediatric oncology (SIOP I). Eur J Cancer 1990;26:464-469.
2. Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572-582.
3. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24:4202-4208.
4. von Hoff K, Hinkes B, Gerber NU, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 2009;45:1209-1217.
5. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 2009;27:385-389.
6. Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med 1994;330:892-895.
7. Bouffet E, Doz F, Demaille MC, et al. Improving survival in recurrent medulloblastoma: Earlier detection, better treatment or still an impasse? Br J Cancer 1998;77:1321-1326.
8. Shih CS, Hale GA, Gronewold L, et al. High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 2008;112:1345-1353.
9. Gururangan S, Krauser J, Watral MA, et al. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology 2008;10:745-751.
10. Dunkel IJ, Gardner SL, Garvin JH, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro-Oncology 2010;12:297-303.
11. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
12. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
13. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
14. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 2010;7:455-465.
15. Chamberlain MC, Grafe MR. Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995;13:2072-2076.
16. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 1997;54:554-558.
17. Asou N, Suzushima H, Nishimura S, et al. Long-term remission in an elderly patient with mantle cell leukemia treated with low-dose cyclophosphamide. Am J Hematol 2000;63:35-37.
18. Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003;98:1643-1648.
19. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-581.
20. Stockklausner C, Behnisch W, Mechtersheimer G, et al. Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide. Pediatr Blood Cancer 2008;50:126-129.
21. Buckstein R, Kerbel RS, Shaked Y, et al. High-dose celecoxib and metronomic "Low-dose" Cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-5198.
22. Krzyzanowska MK, Tannock IF, Lockwood G, et al. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol 2007;60:135-141.
23. André N, Rome A, Coze C, et al. Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: A preliminary monocentric study. Clin Ther 2008;30:1336-1340.
24. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-4905.
25. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the california, chicago, and princess margaret hospital phase II consortia. J Clin Oncol 2008;26:76-82.
26. Sung C-C, Chang P-Y, Cheng M-F, et al. Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma. Ann Hematol 2009;88:1257-1259.
27. Sterba J, Pavelka Z, Andre N, et al. Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatr Blood Cancer 2010;54:616-617.
28. Ashley DM, Meier E, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996;14:1922-1927.
29. Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997;29:28-32.
30. Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-7506.
31. Bergers G, Hanahan D. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol 2002;67:293-300.
32. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-232.
33. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: Single-center pilot study. Onkologie 2006;29:308-313.
34. Panigrahy D, Kaipainen A, Butterfield C, et al. Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med 2010;1:739-746.
35. Robison N, Campigotta F, Chi S, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 2011;57:815.
36. Reismüller B, Azizi AA, Peyrl A, et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer 2010;54:681-686.
37. Macdonald DR, Cascino TL, Schold SC, Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
38. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-3061.
39. Choi LM, Rood B, Kamani N, et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer 2008;50:970-975.
40. Packer RJ. Brain tumors in children. Arch Neurol 1999;56:421-425.